RIG-I Pathway Modulators for Broad-Spectrum Antiviral Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral drugs for RNA viral infections, such as HCV, influenza, and West Nile virus, are limited in effectiveness due to rapid viral resistance and narrow spectrum of action, with most targeting viral proteins rather than the host's innate immune response, leading to side effects and limited treatment options.
Innovation Solution
Development of compounds that modulate the RIG-I pathway, specifically activating or enhancing innate immune signaling to counteract viral countermeasures, thereby targeting the host's antiviral response rather than viral proteins, using methods like luciferase reporter gene assays to identify effective modulators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiviral drugs target viral proteins, then viral infection is treated, but rapid viral resistance and narrow spectrum of action occur
Solution Approach 1:
Instead of targeting viral proteins as conventional drugs do, this invention inverts the approach by targeting the host's RIG-I innate immune signaling pathway. The compounds activate RIG-I signaling to enhance the host's antiviral response, thereby treating viruses without directly interfering with viral proteins, which resolves the contradiction between antiviral effectiveness and viral resistance/spectrum limitations
Solution Approach 2:
The invention identifies compounds that modulate the RIG-I pathway, which is a conserved host defense mechanism against multiple RNA viruses. By targeting this universal host pathway rather than virus-specific proteins, the compounds achieve broad-spectrum antiviral activity against diverse viruses including HCV, influenza, and West Nile virus, eliminating the need for virus-specific targets
2Reliability
If most antiviral drugs target viral proteins, then specific viral infections are treated, but side effects and limited treatment options arise
Solution Approach 1:
The invention inverts the target selection by focusing on the host's RIG-I pathway rather than viral proteins. This approach treats the host's immune response system to clear viruses, avoiding direct interference with viral structures and functions, thereby reducing side effects while maintaining treatment effectiveness across multiple viral infections
3Reliability
If existing antiviral therapies are used, then viral infections are treated, but rapid evolution of viral resistance limits long-term effectiveness
Solution Approach 1:
By targeting the host's RIG-I signaling pathway instead of viral proteins, the compounds create a durable antiviral state through enhanced host immune activation. This approach prevents viral resistance because the host's immune system is activated to clear viruses rather than directly blocking viral replication, ensuring long-term effectiveness
Solution Approach 2:
The invention promotes continuous activation of the RIG-I pathway and downstream interferon signaling, maintaining the host's antiviral state over time. This continuous immune activation prevents viral resurgence and resistance development, ensuring sustained antiviral activity throughout the infection course
Data Source
AI summary
Disclosed herein are methods for identifying compounds for the treatment of viral infection, including RNA viral infection and uses of the compounds as pharmaceutical compositions. The identified compounds modulate the RIG-I pathway in vertebrate cells.